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Purpose. The purpose of this study was to assess the expression of pentose phosphate pathway- (PPP-) related proteins and their
signiﬁcance in clinicopathologic factors of breast cancer. Methods. Immunohistochemical staining for PPP-related proteins
(glucose-6-phosphate dehydrogenase [G6PDH], 6-phosphogluconolactonase [6PGL], 6-phosphogluconate dehydrogenase
[6PGDH], and nuclear factor-erythroid 2-related factor 2 [NRF2]) was performed using tissue microarray (TMA) of 348 breast
cancers. mRNA levels of these markers in publicly available data from the Cancer Genome Atlas project and Kaplan-Meier
plotters were analyzed. Results. Expression of G6PDH and 6PGL was higher in HER-2 type (p < 0 001 and p = 0 009, resp.) and
lower in luminal A type. 6PGDH expression was detected only in TNBC subtype (p < 0 001). G6PDH positivity was associated
with ER negativity (p = 0 001), PR negativity (p = 0 001), and HER-2 positivity (p < 0 001), whereas 6PGL positivity was
associated with higher T stage (p = 0 004). The 562 expression proﬁle from the TCGA database revealed increased expression of
G6PDH and 6PG in the tumor compared with normal adjacent breast tissue. The expression of G6PDH was highest in HER-2
type. HER-2 and basal-like subtypes showed higher expression of 6PGDH than luminal types. Conclusion. PPP-related proteins
are diﬀerentially expressed in breast cancer according to molecular subtype, and higher expression of G6PDH and 6PGL was
noted in HER-2 subtype.
1. Introduction
The pentose phosphate pathway (PPP) is a major glucose
catabolic pathway parallel to glycolysis that is responsible
for synthesis of the nucleotide precursor ribose and nicotin-
amide adenine dinucleotide phosphate (NADPH) required
for glucose metabolism. The PPP consists of an oxidative
branch and a nonoxidative branch. Glucose-6-phosphate
dehydrogenase (G6PDH), 6-phosphogluconolactonase (6PGL),
and 6-phosphogluconate dehydrogenase (6PGDH) are
major proteins involved in the synthesis of NADPH and
ribonucleotide through the oxidative branch. The PPP
provides pentose phosphate required for nucleic acid syn-
thesis in rapidly growing cells. In cancers, the PPP supplies
not only pentose phosphate but also NADPH, which is
important for lipid synthesis and cell survival under stress-
ful circumstances. Thus, the importance of the PPP is
highlighted in rapidly growing cancer cells, and previous
studies have reported that the expression of PPP-related
enzymes is increased in human cancer tissues [1–3].
As breast cancer is a heterogeneous disease in terms of
clinical, histologic, and molecular genetic aspects, a lot of
eﬀort has focused on classifying the disease into subgroups
with similar characteristics. The molecular genetic subtypes
of luminal A, luminal B, HER-2, and normal breast-like
and basal-like type were identiﬁed by gene proﬁling analysis
[4–6]. Separately, breast cancers with a combined negative
expression of estrogen receptor (ER), progesterone receptor
(PR), and human epidermal growth factor receptor 2
(HER-2), which has therapeutic implications, are classiﬁed
as triple-negative breast cancer (TNBC) [7]. This intrinsic
heterogeneity in the molecular genetics of breast cancer gives
rise to heterogeneity in histology, clinical features, treatment
response, and prognosis as well as metabolic features.
Previous studies have reported increased expression of
glycolysis-related proteins GLUT-1 and CAIX in the basal-
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like type and TNBC [8, 9] and increased expression of
glutaminolysis-related proteins in the HER-2 type [10], sug-
gesting a relationship between metabolism and molecular
subtypes of breast cancer. However, there are a limited
number of studies on the expression of pentose phosphate
pathway-related proteins in breast cancer. The objective of
this study was to assess the expression of pentose phosphate
pathway-related proteins according to breast cancer molecu-
lar subtype and their biological and clinical implications.
2. Materials and Methods
2.1. Patient Selection and Histologic Evaluation. Breast cancer
tissues were obtained form 348 patients, who were diagnosed
as invasive ductal carcinoma not otherwise speciﬁed and had
undergone mastectomy at Severance Hospital (Seoul, Repub-
lic of Korea) during the period of January 2001 to December
2006. This study group is selected form previously published
study population [11]. Exclusion criteria were preoperative
chemotherapy or hormonal therapy.
This study was approved by the Institutional Review
Board of Yonsei University Severance Hospital. The IRB
waived the need for informed consent from patients. Breast
pathologist (Ja Seung, Koo) reviewed the histologic features
by using hematoxylin & eosin- (H&E-) stained slides for all
cases. Histologic grade was assessed using the Nottingham
grading system [12]. Clinicopathologic parameters including
patient age at initial diagnosis, lymph node metastasis, tumor
recurrence, distant metastasis, were retrieved from electronic
medical records of each case.
2.2. Tissue Microarray. A TMA construct of 3mm diameter
cores was generated from the 10% neutrally buﬀered
formalin-ﬁxed, paraﬃn-embedded tissue blocks of radical
prostatectomy specimens using a tissue microarrayer. Two
representative cores from diﬀerent cancer areas were
included for each case. Each tissue core was assigned a
unique tissue microarray location number that was linked
to a database containing deidentiﬁed clinicopathologic data.
2.3. Immunohistochemistry. Antibodies used for immuno-
histochemistry are summarized in Table 1. Brieﬂy, repre-
sentative paraﬃn blocks were cut consecutively at 4μm
thickness, and sections were deparaﬃnized in xylene and
treated with 0.3% hydrogen peroxide in methanol for 20
minutes to block any endogenous peroxidase activity. Cit-
rate buﬀer was used for antigen retrieval. Nonspeciﬁc
binding was limited by using protein blocking buﬀer for
10 minutes. The sections were washed in phosphate-buﬀered
saline and then incubated with the primary antibody for 20
minutes at room temperature. The samples were then incu-
bated in secondary antibody (biotinylated) for 10 minutes,
followed by incubation with streptavidin-horseradish peroxi-
dase for 10 minutes, and exposed to diaminobenzidine,
which was used as a chromogen. All labeled streptavidin-
biotin-horseradish peroxidase system chemicals were
obtained from Dako Cytomation Corp. (Carpinteria, CA,
USA). Counterstaining was performed with Mayer’s hema-
toxylin. Negative controls were treated similarly with the
exception of incubation with the primary antibody (nonspe-
ciﬁc staining control).
2.4. Interpretation of Immunohistochemical Staining. All
immunohistochemical markers were evaluated twice by two
independent investigators blinded to the clinical details. Cut-
oﬀ value of 1% or more positively stained nuclei was
employed to deﬁne ER and PR positivity [13]. HER-2 status
was analyzed according to the American Society of Clinical
Oncology (ASCO)/College of American Pathologists (CAP)
guidelines using the following categories: 0 =no immuno-
staining; 1+=weak incomplete membranous staining, less
than 10% of tumor cells; 2+= complete membranous stain-
ing, either uniform or weak in at least 10% of tumor cells;
and 3+=uniform intense membranous staining in at least
30% of tumor cells [14]. HER-2 immunostaining was consid-
ered positive when strong (3+) membranous staining was
observed, whereas cases with 0 to 1+ staining were counted
as negative. Cases showing 2+ HER-2 expression were
further evaluated for HER-2 ampliﬁcation by ﬂuorescent in
situ hybridization (FISH).
Immunohistochemical markers for G6PDH, 6PGL,
6PGDH, and NRF2 were assessed by a semiquantitative eval-
uation method as follows [15]: 0: negative or weak immuno-
staining in <1% of the tumor; 1: focal expression in 1–10%
of the tumor; 2: positive in 11%–50% of the tumor; and 3:
positive in 51%–100% of the tumor. The evaluation was
Table 1: Source, clone, and dilution of antibodies.
Antibody Company Reaction site Clone Dilution
Pentose phosphate pathway-related proteins
G6PDH Abcam, Cambridge, UK Cytoplasmic Polyclonal 1 : 100
6PGL Abcam, Cambridge, UK Cytoplasmic and nuclear ERP1238 (B) 1 : 200
6PGDH Abcam, Cambridge, UK Cytoplasmic Polyclonal 1 : 100
NRF2 Abcam, Cambridge, UK Cytoplasmic and nuclear Polyclonal 1 : 50
Molecular subtype-related proteins
ER Thermo Scientiﬁc, San Diego, CA, USA Nuclear SP1 1 : 100
PR DAKO, Glostrup, Denmark Nuclear PgR 1 : 50
HER-2 DAKO, Glostrup, Denmark Membranous Polyclonal 1 : 1500
Ki-67 Abcam, Cambridge, UK Nuclear MIB 1 : 1000
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made for the whole area of the tumor, and cases with a
score greater than 2 were classiﬁed as positive.
2.5. Tumor Phenotype Classiﬁcation. We classiﬁed each case
breast cancer into molecular phenotype by surrogate immu-
nohistochemistry results for ER, PR, HER-2, Ki-67 labeling
index (LI), and FISH results for HER-2 as follows [16]: lumi-
nal A type, ER or/and PR positive, HER-2 negative, and Ki-67
LI< 14%; luminal B type (HER-2 negative), ER or/and PR
positive, HER-2 negative, and Ki-67 LI≥ 14%; luminal B type
(HER-2 positive), ER or/and PR positive and HER-2 overex-
pressed or/and ampliﬁed; HER-2 overexpression type, ER and
PR negative and HER-2 overexpressed or/and ampliﬁed; and
TNBC type: ER, PR, and HER-2 negative.
2.6. Validation of Expression of PPP-Related Markers in a
Public Database. We obtained clinical information and level
3 normalized gene expression (RSEM) values from RNA
sequencing data of breast cancer (BRCA) from the Broad
Genome Data Analysis Center (GDAC) Firehose server
(version 01-28-2016) and ﬁltered out genes with an expres-
sion equal to zero in more than 50% of samples. PAM50
classiﬁcation information and patient survival information
were also retrieved from the GDAC. We normalized the
value again with the voom function of the limma package
using R software (R version 3.3.1.). Another set of survival
analyses was performed using the Kaplan-Meier plotter [17].
2.7. Statistical Analysis. Statistical analyses were performed
with SPSS for Windows, Version 23.0 (SPSS Inc., Chicago,
IL, USA). Student’s t-test, and Fisher’s exact tests were
employed for continuous and categorical variablefor statisti-
cal signiﬁcance. In case of multiple comparisons, an adjusted
p value with application of the Bonferroni multiple com-
parison procedure was used. p value< 0.05 was considered
to be statistically signiﬁcant. Kaplan-Meier survival curves
and log-rank statistics were employed to evaluate time to
tumor recurrence and overall survival. Multivariate regres-
sion analysis was performed using the Cox proportional
hazard model.
3. Results
3.1. Basal Characteristics of Breast Cancer. The 348 subjects
of this study comprised 162 luminal A (46.6%), 84 luminal
B (24.1), 27 HER-2 type (7.6%), and 75 TNBC (21.6%) sub-
types. TNBC showed higher histologic grade (p < 0 001)
and higher Ki-67 LI (p < 0 001) (Table 2).
Table 2: Clinicopathologic characteristics of patients according to breast cancer phenotype.
Parameter
Total
(n = 348)
(%)
Luminal A
(n = 162)
(%)
Luminal B
(n = 84)
(%)
HER-2
(n = 27)
(%)
TNBC
(n = 75)
(%)
p value
Age (years) 0.299
≤50 202 (58.0) 94 (58.0) 55 (65.5) 13 (48.1) 40 (53.3)
>50 146 (42.0) 68 (42.0) 29 (34.5) 14 (51.9) 35 (46.7)
Histologic grade <0.001
I/II 242 (69.5) 147 (90.7) 53 (63.1) 12 (44.4) 30 (40.0)
III 106 (30.5) 15 (9.3) 31 (36.9) 15 (55.6) 45 (60.0)
Tumor stage 0.068
T1 182 (52.3) 96 (59.3) 42 (50.0) 13 (48.1) 31 (41.3)
T2/T3 166 (47.7) 66 (40.7) 42 (50.0) 14 (51.9) 44 (58.7)
Nodal metastasis 0.676
Absent 208 (59.8) 94 (58.0) 48 (57.1) 17 (63.0) 49 (65.3)
Present 140 (40.2) 68 (42.0) 36 (42.9) 10 (37.0) 26 (34.7)
Estrogen receptor status <0.001
Negative 107 (30.7) 2 (1.2) 3 (3.6) 27 (100.0) 75 (100.0)
Positive 241 (69.3) 160 (98.8) 81 (96.4) 0 (0.0) 0 (0.0)
Progesterone receptor status <0.001
Negative 149 (42.8) 20 (12.3) 27 (32.1) 27 (100.0) 75 (100.0)
Positive 199 (57.2) 142 (87.7) 57 (67.9) 0 (0.0) 0 (0.0)
HER-2 status <0.001
Negative 280 (80.5) 162 (100.0) 43 (51.2) 0 (0.0) 75 (100.0)
Positive 68 (19.5) 0 (0.0) 41 (48.8) 27 (100.0) 0 (0.0)
Ki-67 LI (%) <0.001
≤14 213 (61.2) 162 (100.0) 24 (28.6) 13 (48.1) 14 (18.7)
>14 135 (38.8) 0 (0.0) 60 (71.4) 14 (51.9) 61 (81.3)
TNBC: triple-negative breast cancer.
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Figure 1: Expression of pentose phosphate pathway-related proteins in breast cancer. G6PDH and 6PGL show higher expression in HER-2
type and lower expression in luminal A type. 6PGDH expression is detected only in the TNBC subtype.
Table 3: Expression of pentose phosphate pathway-related metabolism-related proteins according to breast cancer subtype.
Parameter
Total
(n = 348)
(%)
Luminal A
(n = 162)
(%)
Luminal B
(n = 84)
(%)
HER-2
(n = 27)
(%)
TNBC
(n = 75)
(%)
p value
G6PDH <0.001
Negative 297 (85.3) 149 (92.0) 70 (83.3) 14 (51.9) 64 (85.3)
Positive 51 (14.7) 13 (8.0) 14 (16.7) 13 (48.1) 11 (14.7)
6PGL 0.009
Negative 261 (75.0) 133 (82.1) 58 (69.0) 15 (55.6) 55 (73.3)
Positive 87 (25.0) 29 (17.9) 26 (31.0) 12 (44.4) 20 (26.7)
6PGDH <0.001
Negative 343 (98.6) 162 (100.0) 84 (100.0) 27 (100.0) 70 (93.3)
Positive 5 (1.4) 0 (0.0) 0 (0.0) 0 (0.0) 5 (6.7)
NRF2 0.894
Negative 311 (89.4) 145 (89.5) 76 (90.5) 23 (85.2) 67 (89.3)
Positive 37 (10.6) 17 (10.5) 8 (9.5) 4 (14.8) 8 (10.7)
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3.2. Expression of Pentose Phosphate Pathway-Related
Proteins in Breast Cancer. The expression of pentose
phosphate pathway-related proteins was assessed according
to the molecular subtypes of breast cancer (Figure 1).
Expression of G6PDH (p < 0 001), 6PGL (p = 0 009), and
6PGDH (p < 0 001) was identiﬁed; G6PDH and 6PGL
showed higher expression in the HER-2 type and lower
expression in luminal A type. Expression of 6PGDH was
detected only in the TNBC subtype (Table 3).
3.3. Correlation between Expression of Pentose Phosphate
Pathway-Related Proteins and Clinicopathologic Factors.
The expression of pentose phosphate pathway-related
proteins and clinicopathologic parameters was assessed
(Figure 2). G6PDG positivity was associated with ER neg-
ativity (p = 0 001), PR negativity (p = 0 001), and HER-2
positivity (p < 0 001), and 6PGL positivity was associated
with higher T stage (p = 0 004).
3.4. The Impact of Expression of Pentose Phosphate Pathway-
Related Proteins on Patient Prognosis. Univariate analysis
of patient survival did not show statistically signiﬁcant dif-
ferences with regard to expression of pentose phosphate
pathway-related proteins (Table 4).
3.5. Validation of Expression of PPP-Related Markers in a
Public Database. A total of 526 cases were retrieved from
the TCGA study. After normalization, the mRNA level of
each marker was assessed. G6PDH expression was generally
increased in the tumor compared with normal adjacent
breast tissue, and expression was highest in the HER-2 type
compared with other types. 6PGL expression was generally
increased in tumors compared with adjacent normal cells;
however, diﬀerential expression among tumor subtypes was
not identiﬁed. Higher 6PGDH expression compared to
normal tissue was noted in HER-2 and basal-like groups.
The HER-2 type and basal-like subtype showed higher
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Figure 2: Correlation between expression of pentose phosphate pathway-related proteins and clinicopathologic factors. G6PDH positivity is
associated with ER negativity (p = 0 001), PR negativity (p = 0 001), and HER-2 positivity (p < 0 001), and 6PGL positivity is associated with
higher T stage (p = 0 004).
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expression of 6PGDH than luminal types of tumor.
Finally, the expression level of NRF2 was decreased in all
tumor subtypes compared with normal tissue. Univariate
analysis of patient survival with regard to expression of
G6PDG, 6PGL, 6PGDH, and NRF2 did not show statisti-
cal signiﬁcance although there was a tendency toward
longer overall survival with lower expression of 6PGL
and NRF2 in luminal B subtype (p = 0 1092 and p =
0 065, Figure 3(b)). In the cohort of the Kaplan-Meier
plotter, high expression of G6PD was generally related
to longer overall survival and recurrence-free survival
(Figure 3(c)).
4. Discussion
Malignant tumors generally show a rapid growth rate and
invasive traits, which require metabolic remodeling of cancer
cells and stromal cells. As such, the pentose phosphate
pathway is an indispensable metabolic pathway in malignant
tumors because of the demand for a high rate of nucleic
acid synthesis during growth and the NADPH necessary
for cell survival during oncogenic cellular stress. In addi-
tion, reactive oxygen species resulting from the rapidly
increased metabolism may trigger mutation of protoonco-
genes and promote protumorigenic signaling, all of which
aggravate oxidative stress in cancer cells. Thus, a mecha-
nism for activating the oxidative PPP is expected to be
present in cancer cells for maintenance of a high enough
level of NADPH. It is possible that an AMPK-dependent
mechanism also exists given that oxidative PPP is dependent
on glucose availability.
We assessed the expression of PPP-related proteins in
TMAs of human breast cancer tissues and a TCGA data
set and both analyses revealed higher expression in HER-
2 type cancers and lower expression in luminal type can-
cers. A previous study revealed activation of the PPP in
breast carcinoma cells compared with normal breast tis-
sue [18, 19]; this was conﬁrmed in an analysis of the
TCGA data set, which showed increased expression of
PPP-related markers in breast cancer tissue compared with
normal control.
There are few studies on activation of the PPP in
breast cancer. Previous studies on human breast cancer
tissue revealed diﬀerential expression of proteins related
to glycolysis, glutamine metabolism, lipid metabolism, and
serine/glycerine metabolism according to molecular subtype
[9, 10, 20–22], suggesting unique metabolic properties of
each subtype. Generally, subtypes with a high proliferation
rate and aggressive biological behaviors, such as HER-2 or
TNBC types, show increased expression of metabolic
factors [9, 10, 20–22], and comparable results were obtained
in this study. A potential mechanism for higher expression of
PPP markers in the HER-2 type is the relationship of HER-2
with NRF2. A previous study reported association between
NRF2 and HER-2 in the ErbB2/HER-2-positive breast cancer
cell line BT-474 [23], with knockdown of NRF2 leading to
repression of HER-2 expression. As NRF2 is the key molecule
that coordinates the PPP and is known to have a regulatory
role in cancer [24], crosstalk between HER-2 and the PPP
mediated by NRF2 may exist. A second mechanism involves
the fatty acid synthesis pathway in HER-2 type cancer. TP53-
mutated breast cancer shows upregulation of PGD, TK, and
ribose 5-phosphate isomerase A [25]. Previous studies
reported that a high level of transketolase 1 was correlated
with HER-2/neu overexpression [26] and that HER-2 over-
expression increases the translation of fatty acid synthase
and vice versa [27, 28]. Given that NADPH plays a major role
in fatty acid synthesis by fatty acid synthase, HER-2 overex-
pressing tumor cells may use the PPP as a source of NADPH.
It is noticeable that resistance to anti-HER-2 therapy can be
overcome by blockade of the fatty acid synthesis pathway.
Thus, understanding metabolic reprogramming in terms of
the PPP seems clinically relevant.
G6PDH is the rate-limiting enzyme in the PPP and is also
highlighted in this study of breast cancer. G6PDH reﬂects
oxidative PPP and the equilibrium between glycolysis and
the PPP. p53 is a well-known regulator of the PPP through
inhibition of the dimerization and activation of G6PDH
Table 4: Univariate analysis of the impact of expression of pentose phosphate pathway-related proteins in breast cancers on disease-free
survival and overall survival by the log-rank test.
Parameter Number of patients/recurrence/death
Disease-free survival Overall survival
Mean survival (95% CI) months p value Mean survival (95% CI) months p value
G6PDH 0.752 0.377
Negative 297/28/28 126 (122–131) 129 (125–133)
Positive 51/4/7 122 (114–130) 120 (109–131)
6PGL 0.239 0.569
Negative 261/20/24 129 (124–133) 129 (124–133)
Positive 87/12/11 116 (109–124) 125 (117–133)
6PGDH n/a n/a
Negative 343/32/35 n/a n/a
Positive 5/0/0 n/a n/a
NRF2 n/a n/a
Negative 311/32/35 n/a n/a
Positive 37/0/0 n/a n/a
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Figure 3: Validation of expression of pentose phosphate pathway-related proteins in a TCGA cohort and Kaplan-Meier plotter.
(a). Expression of pentose phosphate pathway-related proteins in a TCGA cohort of breast cancer shows increased expression of
G6PDH and 6PGDH. (b). There was a tendency toward longer overall survival with lower expression of 6PGL and NRF2 in the
luminal B subtype (p = 0 109 and p = 0 065) (c). Higher expression of G6PDH is associated with longer overall survival (left) and
disease metastasis-free survival (right) in a Kaplan-Meier plotter cohort.
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[29]. This study revealed a diﬀerence in the expression of
G6PDH among subtypes of breast cancer, and analysis of
the TCGA data showed relatively increased G6PDH levels
in all subtypes of breast tumor compared with normal breast
tissue. Given that expression and activation of G6PDH in
cells are tightly regulated, the increased expression of
G6PDH in breast cancers may reﬂect general activation of
the PPP. Interestingly, increased expression of G6PDH was
most prominent in HER-2 type breast cancers, indicating
transcriptionally regulated expression of G6PDH in this spe-
ciﬁc type of breast cancer.
The role of NRF2 in tumorigenesis is a subject of debate
as activation of NRF2 shows both a tumor suppressor role
and oncogenic roles [30]. The NRF2 level was downregu-
lated in all types of breast cancers in the TCGA dataset,
suggesting a possible role of NRF2 as a tumor suppressor
in breast cancer. However, it is also possible that the result
of RNA sequencing may not reﬂect actual activity of NRF2
in cells due to posttranslational regulation by ubiquitination
and degradation.
The clinical implication of this study is the identiﬁcation
of the PPP protein as a potential therapeutic target. Previous
studies reported that inhibition of PPP proteins resulted
in growth inhibition and cell death in leukemia [31],
ovary cancer [32], urinary bladder cancer [33], and breast
cancer/prostate cancer [34], suggesting that modulation of
this pathway may have therapeutic potential in the treatment
of cancer.
In conclusion, PPP-related proteins are diﬀerentially
expressed according to the molecular subtype of breast
cancer; in particular, G6PDH and 6PGL are highly expressed
in HER-2 type breast cancer. Thus, understanding of the role
of this pathway in breast cancers and further studies on the
eﬀects of targeting this pathway are needed to clarify the
clinical implications of PPP in breast cancers.
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